The U.S. Supreme Court this morning agreed to review a federal appeals court’s July 2020 ruling upholding a nearly 30% reduction in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
The court’s decision to hear American Hospital Association (AHA) v. Becerra was a surprise. The court rejects the vast majority of petitions for review it receives, especially if the petitions do not involve disagreements among federal appeals courts. In addition to AHA, America’s Essential Hospitals, and the American Association of Medical Colleges (AAMC) are the lead plaintiffs along with Henry Ford Health System in Michigan, Northern Light Health in Maine and AdventHealth Hendersonville in North Carolina.
The U.S. Supreme Court this morning agreed to review a federal appeals court’s July 2020 ruling upholding a nearly 30% reduction in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
The court’s decision to hear American Hospital Association (AHA) v. Becerra was a surprise. The court rejects the vast majority of petitions for review it receives, especially if the petitions do not involve disagreements among federal appeals courts. In addition to AHA, America’s Essential Hospitals, and the American Association of Medical Colleges (AAMC) are the lead plaintiffs along with Henry Ford Health System in Michigan, Northern Light Health in Maine and AdventHealth Hendersonville in North Carolina.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.